SUPPLEMENTARY LISTING PARTICULARS
HSBC Bank Middle East Limited
(a company limited by shares incorporated in the Dubai International Financial Centre)
US$7,000,000,000 DEBT ISSUANCE PROGRAMME
This supplement (the "Supplement") to the information memorandum dated 14 July 2016 relating to the US$7,000,000,000 debt issuance programme (the "Programme") of HSBC Bank Middle East Limited (the "Information Memorandum", which constitutes listing particulars for the purposes of listing on the Official List of the Irish Stock Exchange ("Listing") and trading on the Global Exchange Market of the Irish Stock Exchange and, for the avoidance of doubt, which does not constitute (i) a prospectus for the purposes of Part VI of the Financial Services and Markets Act 2000 (as amended) or (ii) a base prospectus for the purposes of Directive 2003/71/EC (as amended)) constitutes supplementary listing particulars (pursuant to rule 3.10 of the Global Exchange Market Listing and Admission to Trading - Rules) for the purposes of Listing.
Terms defined in the Information Memorandum have the same meaning when used in this Supplement.
This Supplement is supplemental to, and should be read in conjunction with, the Information Memorandum.
This Supplement has been approved by the Irish Stock Exchange for the purposes of Listing.
HSBC Bank Middle East Limited (as issuer, the "Issuer") accepts responsibility for the information contained in this Supplement. To the best of the knowledge and belief of the Issuer (having taken all reasonable care to ensure that such is the case), the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.
The purpose of this Supplement is to disclose that the Issuer has published its unaudited interim financial statements for the six-month period ending 30 June 2016 (the "2016 Interim Financial Statements"). A copy of the 2016 Interim Financial Statements is set out in the Annex hereto.
To the extent that there is any inconsistency between (a) any statement in this Supplement and (b) any other statement in or incorporated by reference in the Information Memorandum prior to the date of this Supplement, the statement in this Supplement will prevail.
Save as disclosed in this Supplement, there has been no significant change and no significant new matter has arisen since the publication of the Information Memorandum.
26 September 2016
2016 INTERIM FINANCIAL STATEMENTS
This information is provided by RNS